Uncategorized
Enrollment complete for Glaukos iStent inject pivotal trial
Enrollment in an investigational device exemption trial for the iStent inject is complete, according to a Glaukos press release.The prospective multicenter trial includes 500 patients with glaucoma and cataracts randomized to receive both iStent inject and cataract surgery or to undergo cataract surgery alone. The trial is slated to last 2 years with a primary endpoint of 20% or greater IOP reduction from baseline.